
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies is a high-growth company in the regenerative and aesthetic medicine market. The company's partnership with AbbVie for dermal and soft-tissue fillers provides a strong revenue stream, with potential for considerable growth in the future through milestone payments and royalties. CollPlant's own product candidates also offer promising potential for success in these fields, and tight cost control measures ensure the company's ability to weather near-term development milestones.
Bears say
CollPlant Biotechnologies is facing multiple risks, including reliance on external financing, clinical and regulatory risks, and limited market share. The company's recent transaction at a lower price indicates pressure on equity and a potential for future dilution, while its growing distribution infrastructure and advancements in its rhCollagen technology platform may provide some stability. However, given its current financial position and reliance on partnerships, our outlook for the company's stock remains negative.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares